News about "Glenmark Pharmaceuticals"

Glenmark Pharmaceuticals Launches Vancomycin for Injection USP in US

Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP in the US market, expanding its injectable portfolio in a segment valued at nearly USD 37.9 million annually.

Glenmark Pharmaceuticals | 18/05/2026 | By News Bureau

Glenmark Takes Charge of RYALTRIS Commercialisation in US

Glenmark will handle end-to-end commercialisation and distribution of RYALTRIS nasal spray in the US, strengthening its respiratory portfolio presence.

Glenmark Pharmaceuticals | 06/04/2026 | By News Bureau |  247

Glenmark Pharma USA Launches Generic Milnacipran Tablets

Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride tablets in multiple strengths as the authorised generic of Savella, expanding treatment access in the US market.

Glenmark Pharmaceuticals | 20/03/2026 | By News Bureau

Glenmark Pharma USA Introduces Potassium Phosphates Injection USP

Glenmark Pharmaceuticals USA is set to launch Potassium Phosphates Injection USP in March 2026.

Glenmark Pharmaceuticals | 19/03/2026 | By News Bureau

Glenmark Specialty SA Receives US FDA Approval for Fluticasone Propionate Inhalation Aerosol USP

Glenmark Pharmaceuticals’s subsidiary Glenmark Specialty SA has received approval from the US Food and Drug Administration (FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, along with 180-day Competitive Generic Therapy exclusivity. The product has been deemed bioequivalent and therapeutically equivalent to Flovent HFA.

Glenmark Pharmaceuticals | 05/03/2026 | By Akanki |  127

Glenmark Launches Epinephrine Injection Multi-Dose Vial

Glenmark has introduced its Epinephrine Injection USP, 1?mg/mL, 30?mg/30?mL multiple-dose vial, which is bioequivalent and therapeutically equivalent to the reference drug by BPI Labs, LLC (NDA 205029), offering a reliable alternative for patients and healthcare providers.

Glenmark Pharmaceuticals | 23/12/2025 | By News Bureau |  168

Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma

Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.

Glenmark Pharmaceuticals | 17/12/2025 | By News Bureau |  164

Glenmark's Aurangabad Facility Clears US FDA Inspection With Zero Observations

Glenmark Pharmaceuticals announced that the US Food and Drug Administration (US FDA) has successfully completed a pre-approval inspection of its formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad).

Glenmark Pharmaceuticals | 01/12/2025 | By Dineshwori |  477

Glenmark to Launch 8.4% Sodium Bicarbonate Injection in the US Market

Glenmark Pharmaceuticals has announced its upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial in the US market.

Glenmark Pharmaceuticals | 04/11/2025 | By Dineshwori |  243

Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001

Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.

Glenmark Pharmaceuticals | 09/09/2025 | By Dineshwori |  328